Status and phase
Conditions
Treatments
About
This is a double-blind, randomized, multicenter, placebo-controlled, comparative, exploratory phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 20, 50, or 100 mg ZED1227 vs. placebo for the treatment of patients with NAFLD with fibrosis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
186 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Judith Czarnecki, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal